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left-sided IE and RSIE, therefore a systematic survey of hospital records was per-
formed. For patients with non-device-RSIE the following variables were recorded:
demographic data and risk factors, admission days, associated microorganisms,
complications (abscesses, septic embolisms) and spondylodiscitis.
Results: We identified 1.195 patients in four hospitals; 66 (5.5%) had non-
device-RSIE. Baseline characteristics for non-device-RSIE are shown in the table.
Twenty-seven (41%) non-device-RSIE occurred among people who inject drugs
(PWID). Overall, the tricuspid valve was affected in 43 patients (65%) but in 96%
of PWID. Six patients (one PWID) also had affection of left-sided valves. Con-
genital heart defects were the primary risk factor for non-PWID population with
RSIE (31%). Blood cultures were positive in 59 (89%) patients. Staphylococcus
aureus predominated (52%) and was more common among PWID compared with
non-PWID (p=0.014).
Abscesses and septic embolisms were more frequently seen in PWID (p=0.0001).
Staphylococcus aureus was more frequently associated with occurrence of ab-
scess or septic embolism (p=0.002).
Conclusion: Non-device-RSIE was rare and often, but not always associated
with PWID (41%). Staphylococcus aureus was the most common microorganism
and was associated with abscesses and septic embolisms.
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Introduction: Infection of ascending aortic graft (AAG) is a rare entity whose
diagnosis and treatment remains challenging. Our aim was to evaluate the epi-
demiological, microbiological and clinical characteristics, and outcome of patients
with AAG infection.
Methods: From 1997 to 2017, 1525 episodes of infective endocarditis (IE) were
prospectively recruited in 3 tertiary care centres, of which 264 patients had pros-
thetic aortic valve IE and were classified into two groups: group I (n=230) included
patients with prosthetic aortic valve IE, and group II (n=34), those with prosthetic
aortic valve and AAG IE.
Results: Age distribution was similar in both groups (67.7 vs 66.2 years-old;
p=0.528), and the proportion of men was significantly higher in group II (66.9%
vs 91.2%; p=0.004). Most patients in both groups met definite Duke criteria for IE
(94.8% vs 88.2%; p=0.135). The proportion of patients with mechanical (54.8%
vs 58.8%; p=0.658) and biological aortic prosthesis (45.2% vs 41.2%; p=0.658)
was similar in the two groups. In patients with AAG, 21 (61.8%) had a Bentall and
De Bono procedure, while 13 (38.2%) had a supracoronary aortic graft.
Regarding comorbidities, patients from group I had more frequently diabetes
(21.3% vs 5.9%; p=0.034), chronic anemia (22.6% vs 8.8%; p=0.065) and chronic
renal failure (18.2% vs 8.8%; p=0.172). A previous dental manipulation as pos-
sible portal of entry was more commonly found in group II (1.3% vs 12.1%;
p<0.001). In addition, viridans group streptococci were more frequently isolated
in group II (7.0% vs 17.7%; p=0.035). Both, coagulase-negative staphylococci
(29.1% vs 17.7%; p=0.162) and S. aureus (14.7% vs 14.7%; p=0.991) episodes
were similar in both groups.
Periannular complications (47.8% vs 55.9%; p=0.380), development of heart fail-
ure (23.9% vs 14.7%; p=0.232), and septic shock (19.1% vs 17.7%; p=0.837)
were similar in both groups. Conversely, acute renal failure (17.4% vs 32.4%;
p=0.039), and central nervous system embolisms (10.0% vs 20.6%; p=0.071)
were more frequent in group II.
The percentage of patients who underwent surgery was similar in both groups
(61.8% vs 67.6%; p=0.497), and no significant differences were found regarding
EuroSCORE I (39.6% vs 38.4%; p=0.909) or EuroSCORE II (18.9% vs 28.1%;
p=458).
Distribution of microorganisms
Interestingly, in-hospital mortality was significantly lower in group II (42.5% vs
17.7%, p=0.006), regardless if the infection was managed conservatively (51.2%
vs 18.2%, p=0.039) or surgically (37.3% vs 17.4%; p=0.062).
Conclusions: Patients with prosthetic aortic valve and AAG IE are more often
male, have less comorbidities and are more frequently infected by viridans group
streptococci than patients with isolated prosthetic aortic valve IE. Despite sim-
ilar perioperative risk and rates of surgery, patients with AAG and aortic valve
prosthesis infection had lower in-hospital mortality.
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Introduction: There has been a paradigm shift in management and operative
strategies in Infective Endocarditis (IE). Early and accurate diagnosis of IE is cru-
cial because delayed treatment negatively affects outcome. Therefore, in 2008,
our institution implemented a policy; early echocardiography in suspected IE
cases with aim of early diagnosis and treatment and thus reducing mortality.
Methods: We retrospectively evaluated case notes, echocardiographic and mi-
crobiological data for all patients with IE admitted to our institution from 1998
to 2017. Patients were classified in two groups: 10 years before [Grp1, 1998 to
2007] and 10 years after [Grp2, 2008 to 2017] the policy implementation. Out-
come measures were all-cause in-patient and 30-day mortality.
Results: All groups had similar gender distribution while patients from Grp2 were
younger (66.2±3.2 vs. 49.3±2.2 years). Diabetes and end stage renal failure were
highly prevalent (32.8%) in overall cohort. In Grp1, the mitral valve was most com-
monly affected, however in Grp2, there were a higher proportion of cases affecting
the aortic valve. A similar shift was also noted in the causative microorganism (a
- hemolytic streptococcus (n=77) in Grp 1 vs staphylococcus aureus (n=70) in
Grp 2). Implementation of the policy resulted in a reduction in mortality and also
patients requiring intensive care unit admission [Table 1]. In addition, there ap-
pears to be a reduction in patients requiring surgical intervention in both groups.
Predictors of mortality include staphylococcus aureus (OR 5 95% CI 1.02–23.07
P=0.03), acute kidney injury on admission (OR 5 95% CI 1.02–23.07 P=0.03) and
echocardiographic evidence of vegetation size>15mm (OR 5 95% CI 1.06–23.10
P=0.05)
Table 1. Patient’s demographic, surgical Intervention, ICU admission and mortality from 1998 to
2017
Group 1 (n=140) Group 2 (n=168)
Diabetes 88 (62.8%) 94 (55.9%)
End stage renal failure 32 (22.8%) 61 (36.3%)
Mitral 94 (67.1%) 81 (48.2%)
Aortic 33 (23.5%) 67 (39.9%)
Vegetation size >15mm 21 (26.9%) 25 (28.4%)
a - hemolytic streptococcus 77 (55%) 57 (33.9%)
Staphylococcus aureus 48 (34.2%) 70 (41.6%)
Surgical Intervention 63 57
ICU admission 48 32
In-hospital mortality (days) 42 30
30 day mortality (days) 36 15
Conclusion: Our study demonstrates that mortality and ICU admission were re-
duced after the implementation of early imaging policy. On this basis a high qual-
ity echocardiogram should be performed as soon as possible especially when in
case of prosthetic material or when a complication is suspected
TREATMENT ASPECTS OF HYPERTROPHIC
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Introduction: Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin
II receptor blockers (ARB) are not considered disease-modifying drugs in hyper-
trophic cardiomyopathy (HCM) and their use is usually dependent on other clini-
cal indications. Few data exist about the use of ACEI/ARB in HC in the real world,
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Objective: In this study, we sought to determine the frequency of ACEI / ARB
therapy in patients with HCM and the predictors for their use.
Methods: We analyzed data of patients included in a large National Registry
of adults with HCM and evaluated the associations of ACEI/ARB therapy with
different clinical and echocardiographic variables.
Results: Among 1021 patients with HC, 397 (39%) were medicated with ACEI
and/or ARB. Of these, the majority had hypertension (85%) and asymmetric left
ventricular (LV) hypertrophy (86%), 38% had an intraventricular dynamic obstruc-
tion and 10% had LV systolic dysfunction. Symptoms of heart failure at first visit
were present in 67% of those under ACEI/ARB and concomitant coronary heart
disease was present in 9.2%. In multivariate analysis, the use of ACEI / ARB was
associated with the presence of hypertension (b= 4,44; P=0,00) and LV systolic
dysfunction (b=1,86; p=0,04), and negatively related with intraventricular gradient
(b=-0,95; p=0,02) and abnormal blood pressure response in treadmill test (b=-
1,09; p=0,04).
Conclusion: Even in the absence of specific recommendations, ACEI/ARB are
frequently used in patients with HCM, including in the presence of an intraventric-
ular gradient, suggesting good tolerability. The main factors favoring their use in
clinical practice are the coexistence of hypertension and LV systolic dysfunction.
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Background: Although Dysopiramide has been widely used since the late 1980s
to reduce the degree of obstruction and to improve symptoms in patients with
obstructive hypertrophic cardiomyopathy (HCM), few studies have evaluated its
efficacy and safety. Specifically, the extent of the prolongation of the QT interval
and its implications on patient safety remains controversial.
Purpose: To determine the efficacy of dysopiramide in reducing symptoms and
LVOTO gradients and its safety profile in patients with obstructive HCM.
Methods: From 1980 to 2016, 1644 patients with HCMwere evaluated at our cen-
ter. Of these, 372 (23%) had a left ventricular outflow tract obstruction (LVOTO)
with active follow-up. The efficacy and safety of the use of pharmacological ther-
apy with Disopiramide was assessed systematically by follow-up with repeated
cardiological visits including ECG and echocardiography.
Results: Of the 372 patients with LVOTO obstruction, 118 (80 males, 55±16
years) underwent therapy with dysopyramide at the initial 250 mg dose in ad-
dition to beta blocker/calcium channel blocker therapy. One hundred and eleven
(94%) patients presented functional limitations (NYHA> I) at the beginning of
therapy and a resting LVOTO of 72±36 mmHg. After 7 [3; 25] months in therapy,
a significant improvement of the functional class occurred. Specifically, 5 (5%)
patients in NYHA II class, became asymptomatic; 21 (25%) patients improved
their functional class from NYHA III to NYHA II. The effect on symptoms did not
differ in patients who took a dose of 250 mg/day vs higher doses (p=0.79). Mean
LVOTO gradient at rest post-therapy was not abolished but was significantly re-
duced (49±31 mmHg; p<0.001). During the therapy the median lengthening of
the QTc interval was 21 [2; 32] msec. Specifically, 10 (15%) patients reduced
QTc from baseline (mean reduction 9±6 msec (10 [8; 14]), 10 had no difference,
while 44 (69%) patients prolonged QTc interval of 27 [19; 37] msec. Patients who
presented a QTc <480 msec (46/64) at baseline prolonged more the interval with
respect to the 18/64 patients who had a baseline QTc>480 (24 [7; 35] vs 5 [2; 11]
(p<0.001) msec). Thirty-one (26%) patients experienced side effects, in particu-
lar 29 of anticholinergic type. No patients experienced either complex ventricular
arrhythmias nor syncopal events due to arrhythmic genesis.
Conclusions: Dysopyramide was effective in reducing symptoms and LVOTO
gradients in patients with obstructive HCM. The drug also carried a safe pro-
arrhythmic profile in patients with a relatively small number of side effects. Dysopi-
ramide remains a useful tool in expert hands, especially in patients in whom atrial
fibrillation has to be controlled and the use of amiodarone is contraindicated.
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Objective: The purpose of this study was to to summarize the perioperative man-
agement strategies and early results of modified Morrow operation and coronary
artery bypass grafting (CABG) in patients with obstructive hypertrophic cardiomy-
opathy (HOCM) and coronary atherosclerotic heart disease.
Methods: Between June 2013 and June 2017, in Fu Wai Hospital, 22 patients
underwent modified Morrow operation and coronary artery bypass grafting. The
median age at procedure was 55.4±9.5 years (interquartile range 37 to 67 years).
Preoperative chest distress symptoms in 16 cases, chest pain symptoms in 9
cases, history of syncope in 4 cases. The preoperative left ventricular outflow
tract peak pressure difference (LVOTG) was 55.4±9.5 years (interquartile range
45 to 152) to 152 (82.17±29.61) mmHg (1mmHg=0.133kPa). All patients under-
went modified and expanded Morrow combined with CABG. 3 patients underwent
myocardial bridge releasing in the same period, mitral valve replacement in 2 pa-
tient, mitral valve angioplasty in 1 patients, Maze operation in 1 patient and tricus-
pid valveoplasty in 2 patients. Cardiac echocardiography, electrocardiogram, MRI
were performed routinely after operation and follow-up to analyze structure and
function of heart and mitral valve.
Results: There was no hospital mortality. CABG in patients with branches in-
clude anterior descending artery in 18 cases, diagonal branch in 11 cases, left
circumflex in 6 cases, right coronary artery in 8 cases. There were 10 patients
with one CABG bridge number, 3 patients with two bridge numbers, and 9 pa-
tients with 3 bridge numbers. The average CABG count was 1.8±0.7. The post-
operative ICU time ranged from 1 to 13 days (3.8±3.2 days) and postoperative
hospital stay ranged from 7 to 30 (12.2±5.4 days). No severe postoperative com-
plications were found and 1 case had postoperative incision healing. The postop-
erative new arrhythmia including left bundle branch block in 3 cases. Compared
with the preoperative values, Postoperative left ventricular outflow tract peak pres-
sure (82.17±29.61 mmHg vs 11.22±5.49 mmHg, P=0.00), interventricular septum
thickness (17.8±3.7 mm vs 13. 6±5.3 mm, P=0.00) were decreased obviously. Mi-
tral valve closure is good, mitral valve forward movement (SAM sign) disappeared.
The patients were followed up for 4–48 months, with an average of (22.3±10.4)
months. All patients were followed up with symptoms disappeared or only mild
symptoms. NYHA classification decreased I to II grade after surgery, without long-
term mortality, complications or reoperation.
Conclusions: For patients with obstructive hypertrophic cardiomyopathy with
coronary atherosclerotic heart disease, the application of improved expand mor-
row operation at the same time undergoing coronary artery bypass grafting is
safe. This can significantly improve patient survival and reduce symptoms, play a
synergistic effect, and does not increase the patient’s surgical complications.
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Background: Alcohol septal ablation (ASA) and septal myectomy (SM) are 2 op-
tions of septal reduction therapy (SRT) for patients with obstructive hypertrophic
cardiomyopathy (HCM). SM has been regarded as the first-line choice for SRT,
while ASA is gaining popularity over the last decade. The literature has docu-
mented that the degree of symptomatic relief and reduction in left ventricular out-
flow tract obstruction is less with ASA compared to SM, however scarce data exist
as to whether such differences are translated into differential risks of acute care
use for cardiovascular disease (CVD).
Purpose: To test the hypothesis that patients with HCMwho underwent ASA have
higher risks of acute care use (i.e., emergency department [ED] visit or unplanned
hospitalization) for CVD than those who underwent SM.
Methods: We performed a comparative effectiveness study of ASA versus SM
among patients with HCM who underwent SRT, using population-based ED and
inpatient databases in California, Florida, and Nebraska from 2005 through 2014.
These databases captured all ED visits and hospitalizations within the study
states. The outcome was acute care use for CVD during a 2-year post-SRT pe-
riod. We constructed logistic regression models with generalized estimating equa-
tions to compare the risk of outcome during sequential 6-month periods, using SM
group as the reference. We conducted univariable and multivariable analyses ad-
justing for age, sex, race/ethnicity, insurance type, household income, season and
year of surgery, state, and Elixhauser comorbidity measures. We also performed
sensitivity analysis with propensity score (PS)-matching at 1:1 ratio using these
variables.
Results: We identified 850 patients with HCM who underwent SRT, including
393 with ASA and 457 with SM. At baseline, patients who underwent ASA had
a significantly lower prevalence of heart failure, valvular heart disease, hyperten-
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